Protein-Protein Interactions in Drug Discovery

Treating protein-protein interactions as a novel and highly promising class of drug targets, this volume introduces the underlying strategies step by step, from the biology of PPIs to biophysical and computational methods for their investigation.
The main part of the book describes examples of protein targets for which small molecule modulators have been developed, covering such diverse fields as cancer, autoimmune disorders and infectious diseases. Tailor-made for the practicing medicinal chemist, this ready reference includes a wide selection of case studies taken straight from the development pipeline of major pharmaceutical companies to illustrate the power and potential of this approach.

From the contents:

* Prediction of intra- and inter-species protein-protein interactions facilitating systems biology studies
* Modulators of protein-protein interactions: The importance of Three-Dimensionality
* Interactive technologies for leveraging the known chemistry of anchor residues
* SH3 Domains as Drug Targets
* P53 MDM2 Antagonists: Towards Non Genotoxic Anticancer Treatments
* Inhibition of LFA-1/ICAM interaction for treatment of autoimmune diseases
* The PIF-binding pocket of AGC kinases
* Peptidic inhibitors of protein-protein interactions for cell adhesion receptors
* The REPLACE Strategy for generating Non-ATP competitive Inhibitors of Cell-Cycle Protein Kinases

and more

Avainsanat: protein-protein interactions in drug discovery, protein-protein interactions, drug discovery, protein-protein, drug targets, medicinal chemist, cancer, autoimmune disorders, infectious diseases, pharmaceutical companies, small molecule modulators, protein targets, PPIs, small molecule ligands, molecule ligands, Alexander Dömling, biochemistry, biophysicists, biotechnologists, blockbuster drugs, development pipeline, intra-species, inter-species, systembs biology, Prediction of intra- and inter-species, Modulators of protein-protein interactions, Protein-Protein Interaction inhibitors, SH3 Domains as Drug Targets, P53 MDM2 Antagonists, Inhibition of LFA-1/ICAM interaction, PIF-binding pocket of AGC kinases, Retosiban, Epelsiban, Oxytocin Antagonists, Peptidic inhibitors, cell adhesion receptors, RGD peptides, REPLACE Strategy, Non-ATP competitive Inhibitors, Cell-Cycle Protein Kinases, protein science, biotechnology, drug development, Protein Science, Biotechnology (Life Sciences), Protein Science, Biotechnology (Life Sciences)